Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis

Acta Haematologica

Volumn 119, Issue 1, 2008, Pages 40-44

  Voskaridou, Ersi ^a   Christoulas, Dimitrios ^b   Antoniadou, Lito ^c   Terpos, Evangelos ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b General Air Force Hospital   (Greece)

^c BIOIATRIKI HEALTHCARE GROUP   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ERYTHROPOIETIN; ESTRADIOL; MEDROXYPROGESTERONE; TESTOSTERONE ENANTATE; ZOLEDRONIC ACID;

ADULT; ARTICLE; BETA THALASSEMIA; BONE DENSITY; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; ERYTHROPOIESIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THALASSEMIA; TREATMENT DURATION;

ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ERYTHROPOIESIS; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPOROSIS; THALASSEMIA;

EID: 40549136796     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000114869     Document Type: Article

References (18)

1. Cazzola M, Pootrakul P, Huebers HA, Eng M, Eschbach J, Finch CA: Erythroid marrow function in anemic patients. Blood 1987;69:296-301.
2. Pootrakul P, Hungsprenges S, Fucharoen S, Baylink D, Thompson E, English E, Lee M, Burnell J, Finch C: Relation between erythropoiesis and bone metabolism in thalassemia. N Engl J Med 1981;304:1470-1473.
3. Wonke B: Bone disease in β-thalassaemia major. Br J Haematol 1998;103:897-901.
4. Voskaridou E, Terpos E: New insights into the pathophysiology and management of osteoporosis in patients with β thalassaemia. Br J Haematol 2004;127:127-139.
5. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D: Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001;112:36-41.
6. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D: Pamidronate is an effective treatment for osteoporosis in patients with β-thalassaemia. Br J Haematol 2003;123:730-737.
7. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E: Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a singlecenter, randomized, placebo-controlled trial. Haematologica 2006;91:1193-1202.
8. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y: Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998;91:2139-2145.
9. Beguin Y: Soluble transferring receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22.
10. Melzack R: The McGill pain questionnaire: major properties and scoring methods. Pain 1975;1:275-279.
11. Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, Crawford BA: A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 2006;79:138-144.
12. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F: Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 2007;86:23-30.
13. Mahachoklertwattana P, Pootrakul P, Chuansumrit A, Choubtum L, Sriphrapradang A, Sirisriro R, Rajatanavin R: Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab 2006;24:146-152.
14. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N: Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004;19:722-727.
15. Voskaridou E, Terpos E: Osteoprotegerin to soluble receptor activator of nuclear factor κB ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol 2005;74:359-361.
16. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, Franchina F, Maisano D, La Rosa M, Plota M, Crifo A, Meo A, Frisina N: The 'lively' cytokines network in β-thalassemia major-related osteoporosis. Bone 2007;40:1588-1594.
17. Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, Barella S, Cao A, Galanello R: Relationship between transfusion regimen and suppression of erythropoesis in β-thalassaemia major. Br J Haematol 1995;89:473-478.
18. Aessopos A, Kati M, Meletis J: Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion 2007;47:792-800.